These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 26108538)
1. Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats. Gonzalez Y; Pokrzywinski KL; Rosen ET; Mog S; Aryal B; Chehab LM; Vijay V; Moland CL; Desai VG; Dickey JS; Rao VA Cancer Chemother Pharmacol; 2015 Sep; 76(3):447-59. PubMed ID: 26108538 [TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats. Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135 [TBL] [Abstract][Full Text] [Related]
3. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats. Sharkey LC; Radin MJ; Heller L; Rogers LK; Tobias A; Matise I; Wang Q; Apple FS; McCune SA Toxicol Appl Pharmacol; 2013 Nov; 273(1):47-57. PubMed ID: 23993975 [TBL] [Abstract][Full Text] [Related]
4. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats. Rao VA; Zhang J; Klein SR; Espandiari P; Knapton A; Dickey JS; Herman E; Shacter EB Cancer Chemother Pharmacol; 2011 Nov; 68(5):1125-34. PubMed ID: 21373894 [TBL] [Abstract][Full Text] [Related]
5. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice. Vijay V; Moland CL; Han T; Fuscoe JC; Lee T; Herman EH; Jenkins GR; Lewis SM; Cummings CA; Gao Y; Cao Z; Yu LR; Desai VG Toxicol Appl Pharmacol; 2016 Mar; 295():68-84. PubMed ID: 26873546 [TBL] [Abstract][Full Text] [Related]
6. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Herman EH; Lipshultz SE; Rifai N; Zhang J; Papoian T; Yu ZX; Takeda K; Ferrans VJ Cancer Res; 1998 Jan; 58(2):195-7. PubMed ID: 9443390 [TBL] [Abstract][Full Text] [Related]
7. Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats. Todorova VK; Kaufmann Y; Hennings LJ; Klimberg VS Cancer Chemother Pharmacol; 2010 Jul; 66(2):315-23. PubMed ID: 19898822 [TBL] [Abstract][Full Text] [Related]
8. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity. Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411 [TBL] [Abstract][Full Text] [Related]
9. General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid. Ghibu S; Delemasure S; Richard C; Guilland JC; Martin L; Gambert S; Rochette L; Vergely C Biochimie; 2012 Apr; 94(4):932-9. PubMed ID: 21396425 [TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and myocardial gene alterations associated with Doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation. Richard C; Ghibu S; Delemasure-Chalumeau S; Guilland JC; Des Rosiers C; Zeller M; Cottin Y; Rochette L; Vergely C J Pharmacol Exp Ther; 2011 Dec; 339(3):807-14. PubMed ID: 21934029 [TBL] [Abstract][Full Text] [Related]
11. Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Bagchi AK; Malik A; Akolkar G; Zimmer A; Belló-Klein A; De Angelis K; Jassal DS; Fini MA; Stenmark KR; Singal PK Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119039. PubMed ID: 33857568 [TBL] [Abstract][Full Text] [Related]
12. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Thompson KL; Rosenzweig BA; Zhang J; Knapton AD; Honchel R; Lipshultz SE; Retief J; Sistare FD; Herman EH Cancer Chemother Pharmacol; 2010 Jul; 66(2):303-14. PubMed ID: 19915844 [TBL] [Abstract][Full Text] [Related]
13. Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Hazari MS; Haykal-Coates N; Winsett DW; Costa DL; Farraj AK Toxicol Sci; 2009 Jul; 110(1):224-34. PubMed ID: 19407338 [TBL] [Abstract][Full Text] [Related]
14. Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin. Segredo MP; Salvadori DM; Rocha NS; Moretto FC; Correa CR; Camargo EA; de Almeida DC; Reis RA; Freire CM; Braz MG; Tang G; Matsubara LS; Matsubara BB; Yeum KJ; Ferreira AL Hum Exp Toxicol; 2014 Jul; 33(7):748-60. PubMed ID: 24275640 [TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane does not protect against doxorubicin-induced damage in young rats. Héon S; Bernier M; Servant N; Dostanic S; Wang C; Kirby GM; Alpert L; Chalifour LE Am J Physiol Heart Circ Physiol; 2003 Aug; 285(2):H499-506. PubMed ID: 12714334 [TBL] [Abstract][Full Text] [Related]
16. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Forrest GL; Gonzalez B; Tseng W; Li X; Mann J Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643 [TBL] [Abstract][Full Text] [Related]